TrialJournal of diabetes investigation2021

Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.

Fuqiang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.